Shopping Cart 0
Cart Subtotal
AED 0

Keryx Biopharmaceuticals Inc (KERX)-Financial and Strategic SWOT Analysis Review

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 459

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 918

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 1376

Details

Keryx Biopharmaceuticals Inc (KERX)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Keryx Biopharmaceuticals Inc (Keryx) develops and commercializes new therapies for the treatment of renal disease. The company's lead product Auryxia (ferric citrate) is an FDA approved oral, absorbable iron-based compound. It has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. Auryxia is used in the treatment of chronic kidney disease, renal diseases and iron deficiency anemia. This product is also marketed in Japan under the brand name Riona through its Japanese partner Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd, and in Europe as Fexeric. The company operates through its subsidiaries and also has its operational presence with its offices located in Israel, the US, and the UK. Keryx is headquartered in New York, the US.

Keryx Biopharmaceuticals Inc Key Recent Developments

Mar 01,2017: Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results

Nov 09,2016: Keryx Biopharmaceuticals Announces Third Quarter 2016 Financial Results and Provides Corporate Update

Aug 01,2016: Keryx Biopharmaceuticals Announces Second Quarter 2016 Financial Results

Jun 27,2016: Douglas Jermasek to Join Keryx Biopharmaceuticals as Vice President, Marketing and Strategy

Jun 21,2016: Keryx Biopharmaceuticals Appoints Two New Board Members

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Section 1-About the Company 5

Keryx Biopharmaceuticals Inc-Key Facts 5

Keryx Biopharmaceuticals Inc-Key Employees 6

Keryx Biopharmaceuticals Inc-Key Employee Biographies 7

Keryx Biopharmaceuticals Inc-Major Products and Services 8

Keryx Biopharmaceuticals Inc-History 9

Keryx Biopharmaceuticals Inc-Company Statement 11

Keryx Biopharmaceuticals Inc-Locations And Subsidiaries 13

Head Office 13

Other Locations & Subsidiaries 13

Section 2-Company Analysis 14

Keryx Biopharmaceuticals Inc-Business Description 14

Keryx Biopharmaceuticals Inc-Corporate Strategy 15

Keryx Biopharmaceuticals Inc-SWOT Analysis 16

SWOT Analysis-Overview 16

Keryx Biopharmaceuticals Inc-Strengths 16

Keryx Biopharmaceuticals Inc-Weaknesses 17

Keryx Biopharmaceuticals Inc-Opportunities 18

Keryx Biopharmaceuticals Inc-Threats 19

Keryx Biopharmaceuticals Inc-Key Competitors 20

Section 3-Company Financial Ratios 21

Financial Ratios-Capital Market Ratios 21

Financial Ratios-Annual Ratios 22

Performance Chart 24

Financial Performance 24

Financial Ratios-Interim Ratios 25

Financial Ratios-Ratio Charts 26

Section 4-Company's Lifesciences Financial Deals and Alliances 27

Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 27

Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 28

Keryx Biopharmaceuticals Inc, Recent Deals Summary 29

Section 5-Company's Recent Developments 30

Mar 01, 2017: Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results 30

Nov 09, 2016: Keryx Biopharmaceuticals Announces Third Quarter 2016 Financial Results and Provides Corporate Update 32

Aug 01, 2016: Keryx Biopharmaceuticals Announces Second Quarter 2016 Financial Results 34

Jun 27, 2016: Douglas Jermasek to Join Keryx Biopharmaceuticals as Vice President, Marketing and Strategy 35

Jun 21, 2016: Keryx Biopharmaceuticals Appoints Two New Board Members 36

Apr 28, 2016: Keryx Biopharmaceuticals Announces First Quarter 2016 Financial Results 37

Apr 01, 2016: Keryx Biopharmaceuticals Announces New Appointments and Changes to its Board of Directors 39

Feb 25, 2016: Keryx Biopharmaceuticals Announces Fourth Quarter and Year-End 2015 Financial Results 40

Section 6-Appendix 42

Methodology 42

Ratio Definitions 42

About GlobalData 46

Contact Us 46

Disclaimer 46


List Of Figure

List of Figures

Keryx Biopharmaceuticals Inc, Performance Chart (2012-2016) 24

Keryx Biopharmaceuticals Inc, Ratio Charts 26

Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 27

Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 28


List Of Table

List of Tables

Keryx Biopharmaceuticals Inc, Key Facts 5

Keryx Biopharmaceuticals Inc, Key Employees 6

Keryx Biopharmaceuticals Inc, Key Employee Biographies 7

Keryx Biopharmaceuticals Inc, Major Products and Services 8

Keryx Biopharmaceuticals Inc, History 9

Keryx Biopharmaceuticals Inc, Subsidiaries 13

Keryx Biopharmaceuticals Inc, Key Competitors 20

Keryx Biopharmaceuticals Inc, Ratios based on current share price 21

Keryx Biopharmaceuticals Inc, Annual Ratios 22

Keryx Biopharmaceuticals Inc, Annual Ratios (Cont...1) 23

Keryx Biopharmaceuticals Inc, Interim Ratios 25

Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 27

Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 28

Keryx Biopharmaceuticals Inc, Recent Deals Summary 29

Currency Codes 42

Capital Market Ratios 42

Equity Ratios 43

Profitability Ratios 43

Cost Ratios 44

Liquidity Ratios 44

Leverage Ratios 45

Efficiency Ratios 45

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Onyx Pharmaceuticals Inc, Millennium Pharmaceuticals Inc, Genzyme Corp, Fresenius Medical Care AG & Co KGaA, Astex Pharmaceuticals Inc, Akebia Therapeutics Inc

Company Profile

Company Profile Title

Keryx Biopharmaceuticals Inc (KERX)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Keryx Biopharmaceuticals Inc (Keryx) develops and commercializes new therapies for the treatment of renal disease. The company's lead product Auryxia (ferric citrate) is an FDA approved oral, absorbable iron-based compound. It has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. Auryxia is used in the treatment of chronic kidney disease, renal diseases and iron deficiency anemia. This product is also marketed in Japan under the brand name Riona through its Japanese partner Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd, and in Europe as Fexeric. The company operates through its subsidiaries and also has its operational presence with its offices located in Israel, the US, and the UK. Keryx is headquartered in New York, the US.

Keryx Biopharmaceuticals Inc Key Recent Developments

Mar 01,2017: Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results

Nov 09,2016: Keryx Biopharmaceuticals Announces Third Quarter 2016 Financial Results and Provides Corporate Update

Aug 01,2016: Keryx Biopharmaceuticals Announces Second Quarter 2016 Financial Results

Jun 27,2016: Douglas Jermasek to Join Keryx Biopharmaceuticals as Vice President, Marketing and Strategy

Jun 21,2016: Keryx Biopharmaceuticals Appoints Two New Board Members

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Section 1-About the Company 5

Keryx Biopharmaceuticals Inc-Key Facts 5

Keryx Biopharmaceuticals Inc-Key Employees 6

Keryx Biopharmaceuticals Inc-Key Employee Biographies 7

Keryx Biopharmaceuticals Inc-Major Products and Services 8

Keryx Biopharmaceuticals Inc-History 9

Keryx Biopharmaceuticals Inc-Company Statement 11

Keryx Biopharmaceuticals Inc-Locations And Subsidiaries 13

Head Office 13

Other Locations & Subsidiaries 13

Section 2-Company Analysis 14

Keryx Biopharmaceuticals Inc-Business Description 14

Keryx Biopharmaceuticals Inc-Corporate Strategy 15

Keryx Biopharmaceuticals Inc-SWOT Analysis 16

SWOT Analysis-Overview 16

Keryx Biopharmaceuticals Inc-Strengths 16

Keryx Biopharmaceuticals Inc-Weaknesses 17

Keryx Biopharmaceuticals Inc-Opportunities 18

Keryx Biopharmaceuticals Inc-Threats 19

Keryx Biopharmaceuticals Inc-Key Competitors 20

Section 3-Company Financial Ratios 21

Financial Ratios-Capital Market Ratios 21

Financial Ratios-Annual Ratios 22

Performance Chart 24

Financial Performance 24

Financial Ratios-Interim Ratios 25

Financial Ratios-Ratio Charts 26

Section 4-Company's Lifesciences Financial Deals and Alliances 27

Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 27

Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 28

Keryx Biopharmaceuticals Inc, Recent Deals Summary 29

Section 5-Company's Recent Developments 30

Mar 01, 2017: Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results 30

Nov 09, 2016: Keryx Biopharmaceuticals Announces Third Quarter 2016 Financial Results and Provides Corporate Update 32

Aug 01, 2016: Keryx Biopharmaceuticals Announces Second Quarter 2016 Financial Results 34

Jun 27, 2016: Douglas Jermasek to Join Keryx Biopharmaceuticals as Vice President, Marketing and Strategy 35

Jun 21, 2016: Keryx Biopharmaceuticals Appoints Two New Board Members 36

Apr 28, 2016: Keryx Biopharmaceuticals Announces First Quarter 2016 Financial Results 37

Apr 01, 2016: Keryx Biopharmaceuticals Announces New Appointments and Changes to its Board of Directors 39

Feb 25, 2016: Keryx Biopharmaceuticals Announces Fourth Quarter and Year-End 2015 Financial Results 40

Section 6-Appendix 42

Methodology 42

Ratio Definitions 42

About GlobalData 46

Contact Us 46

Disclaimer 46


List Of Figure

List of Figures

Keryx Biopharmaceuticals Inc, Performance Chart (2012-2016) 24

Keryx Biopharmaceuticals Inc, Ratio Charts 26

Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 27

Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 28


List Of Table

List of Tables

Keryx Biopharmaceuticals Inc, Key Facts 5

Keryx Biopharmaceuticals Inc, Key Employees 6

Keryx Biopharmaceuticals Inc, Key Employee Biographies 7

Keryx Biopharmaceuticals Inc, Major Products and Services 8

Keryx Biopharmaceuticals Inc, History 9

Keryx Biopharmaceuticals Inc, Subsidiaries 13

Keryx Biopharmaceuticals Inc, Key Competitors 20

Keryx Biopharmaceuticals Inc, Ratios based on current share price 21

Keryx Biopharmaceuticals Inc, Annual Ratios 22

Keryx Biopharmaceuticals Inc, Annual Ratios (Cont...1) 23

Keryx Biopharmaceuticals Inc, Interim Ratios 25

Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 27

Keryx Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 28

Keryx Biopharmaceuticals Inc, Recent Deals Summary 29

Currency Codes 42

Capital Market Ratios 42

Equity Ratios 43

Profitability Ratios 43

Cost Ratios 44

Liquidity Ratios 44

Leverage Ratios 45

Efficiency Ratios 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Onyx Pharmaceuticals Inc, Millennium Pharmaceuticals Inc, Genzyme Corp, Fresenius Medical Care AG & Co KGaA, Astex Pharmaceuticals Inc, Akebia Therapeutics Inc